Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MKNK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MKNK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MKNK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MKNK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MKNK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MKNK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MKNK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MKNK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0097191 | Colorectum | AD | extrinsic apoptotic signaling pathway | 68/3918 | 219/18723 | 2.64e-04 | 3.27e-03 | 68 |
GO:0018105 | Colorectum | AD | peptidyl-serine phosphorylation | 88/3918 | 315/18723 | 1.73e-03 | 1.43e-02 | 88 |
GO:0018209 | Colorectum | AD | peptidyl-serine modification | 92/3918 | 338/18723 | 3.19e-03 | 2.36e-02 | 92 |
GO:00467771 | Colorectum | SER | protein autophosphorylation | 60/2897 | 227/18723 | 1.36e-05 | 4.25e-04 | 60 |
GO:00971911 | Colorectum | SER | extrinsic apoptotic signaling pathway | 58/2897 | 219/18723 | 1.76e-05 | 5.22e-04 | 58 |
GO:00064171 | Colorectum | SER | regulation of translation | 100/2897 | 468/18723 | 3.76e-04 | 5.74e-03 | 100 |
GO:0071243 | Colorectum | SER | cellular response to arsenic-containing substance | 9/2897 | 20/18723 | 1.66e-03 | 1.72e-02 | 9 |
GO:0046685 | Colorectum | SER | response to arsenic-containing substance | 12/2897 | 33/18723 | 2.71e-03 | 2.44e-02 | 12 |
GO:00181051 | Colorectum | SER | peptidyl-serine phosphorylation | 66/2897 | 315/18723 | 5.47e-03 | 4.06e-02 | 66 |
GO:00064172 | Colorectum | MSS | regulation of translation | 134/3467 | 468/18723 | 4.43e-08 | 2.38e-06 | 134 |
GO:00971912 | Colorectum | MSS | extrinsic apoptotic signaling pathway | 63/3467 | 219/18723 | 1.34e-04 | 2.03e-03 | 63 |
GO:00467772 | Colorectum | MSS | protein autophosphorylation | 63/3467 | 227/18723 | 3.96e-04 | 4.91e-03 | 63 |
GO:00181052 | Colorectum | MSS | peptidyl-serine phosphorylation | 81/3467 | 315/18723 | 8.92e-04 | 9.12e-03 | 81 |
GO:00182091 | Colorectum | MSS | peptidyl-serine modification | 84/3467 | 338/18723 | 2.12e-03 | 1.79e-02 | 84 |
GO:0038034 | Colorectum | MSS | signal transduction in absence of ligand | 22/3467 | 65/18723 | 2.33e-03 | 1.90e-02 | 22 |
GO:0097192 | Colorectum | MSS | extrinsic apoptotic signaling pathway in absence of ligand | 22/3467 | 65/18723 | 2.33e-03 | 1.90e-02 | 22 |
GO:00064174 | Colorectum | FAP | regulation of translation | 111/2622 | 468/18723 | 8.47e-09 | 1.13e-06 | 111 |
GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MKNK2 | SNV | Missense_Mutation | rs756023428 | c.1295N>A | p.Arg432His | p.R432H | Q9HBH9 | protein_coding | tolerated(0.17) | possibly_damaging(0.608) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MKNK2 | SNV | Missense_Mutation | | c.1102N>A | p.Val368Ile | p.V368I | Q9HBH9 | protein_coding | tolerated(0.26) | possibly_damaging(0.491) | TCGA-BK-A139-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MKNK2 | SNV | Missense_Mutation | rs376495867 | c.124N>C | p.Cys42Arg | p.C42R | Q9HBH9 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
MKNK2 | SNV | Missense_Mutation | | c.1057G>A | p.Ala353Thr | p.A353T | Q9HBH9 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MKNK2 | SNV | Missense_Mutation | novel | c.554N>C | p.Val185Ala | p.V185A | Q9HBH9 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
MKNK2 | SNV | Missense_Mutation | novel | c.298N>G | p.Thr100Ala | p.T100A | Q9HBH9 | protein_coding | tolerated(0.07) | benign(0.012) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
MKNK2 | SNV | Missense_Mutation | rs371172997 | c.1354A>G | p.Ser452Gly | p.S452G | Q9HBH9 | protein_coding | deleterious_low_confidence(0.04) | benign(0.164) | TCGA-2Y-A9GU-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MKNK2 | SNV | Missense_Mutation | novel | c.574N>A | p.Ala192Thr | p.A192T | Q9HBH9 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-2Y-A9GZ-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD |
MKNK2 | SNV | Missense_Mutation | novel | c.761N>T | p.Ala254Val | p.A254V | Q9HBH9 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-G3-AAV2-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MKNK2 | SNV | Missense_Mutation | novel | c.760N>A | p.Ala254Thr | p.A254T | Q9HBH9 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-G3-AAV2-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | SORAFENIB | SORAFENIB | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | GEFITINIB | GEFITINIB | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 328083468 | | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | ERLOTINIB | ERLOTINIB | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | SNS-314 | SNS-314 | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | LINIFANIB | LINIFANIB | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | TAMATINIB | R-406 | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | CENISERTIB | CENISERTIB | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | ILORASERTIB | ILORASERTIB | |
2872 | MKNK2 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | CYC-116 | CYC-116 | |